Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROMETHAZINE HYDROCHLORIDE PLAIN vs HYDROXYZINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also has anticholinergic, antiemetic, and sedative properties. In the CNS, it inhibits the chemoreceptor trigger zone and vestibular apparatus, contributing to its antiemetic effect.
Hydroxyzine is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract. It also exhibits sedative, anxiolytic, and antiemetic properties, possibly through central nervous system depression and anticholinergic effects.
FDA-approved: Symptomatic management of allergic conditions (e.g., rhinitis, urticaria, pruritus), motion sickness, nausea and vomiting (prevention and treatment), and as a preoperative sedative or adjunct to analgesics.,Off-label: Relief of anxiety, insomnia, and as a sedative-hypnotic.
Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitis,Anxiety and tension (as a short-term management in adults),Preoperative sedation and to reduce anxiety prior to surgery,Nausea and vomiting (off-label),Insomnia (off-label)
Adults: 25 mg orally or intramuscularly every 4 to 6 hours as needed; for motion sickness, 25 mg taken 30-60 minutes before departure, then every 12 hours as needed.
25-100 mg orally 3-4 times daily; 50-100 mg IM every 4-6 hours as needed. Maximum oral dose: 600 mg/day in divided doses.
Terminal elimination half-life is approximately 10-19 hours in adults (mean ~16 hours). In children, half-life is shorter (~7-14 hours). Clinical context: Once-daily dosing may be insufficient for continuous sedation; requires every 6-8 hour dosing for sustained effect.
Terminal elimination half-life: 14-25 hours (mean ~20 h). In elderly or hepatic impairment, may be prolonged; antihistamine effect persists beyond half-life due to active metabolite.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (e GFR <30 m L/min) due to risk of accumulation and CNS adverse effects.
GFR 10-50 m L/min: administer every 12 hours. GFR <10 m L/min: administer every 24 hours. Not recommended for use in patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) due to increased risk of neurotoxicity.
Do not use in children younger than 2 years due to the risk of respiratory depression (including fatal cases). Promethazine should not be used in combination with other respiratory depressants.
Pregnancy category C. First trimester: Potential risk of teratogenicity based on animal studies; human data limited but not associated with major malformations in large cohort studies. Second/third trimester: Use near term may cause respiratory depression, extrapyramidal signs in neonate; avoid during labor due to potential adverse effects on uterine contractility.
Hydroxyzine is generally considered low risk for teratogenicity. Animal studies have shown no consistent evidence of fetal harm. Human data are limited but do not indicate a significant increase in major malformations. In the first trimester, use only if clearly needed. In the second and third trimesters, there is a potential risk of neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near term or in high doses. Avoid use during labor and delivery due to potential maternal hypotension and fetal effects.
Promethazine is a phenothiazine derivative with strong antihistamine (H1) and antiemetic properties. It has significant anticholinergic and sedative effects. Avoid intra-arterial injection due to risk of severe arteriospasm and gangrene. May cause extrapyramidal symptoms, especially in children and elderly. Use with caution in patients with asthma, COPD, or sleep apnea due to respiratory depression. Promethazine can interfere with urine pregnancy tests and blood glucose monitoring.
Hydroxyzine is a first-generation antihistamine with anxiolytic, sedative, and antiemetic properties. It is commonly used for pruritus, anxiety, and premedication. Avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, risk of confusion and falls is increased; consider alternative therapies. Hydroxyzine has anticholinergic effects; use cautiously in patients with glaucoma, urinary retention, or prostatic hyperplasia. Note that hydroxyzine can cause QT prolongation at high doses or in combination with other QT-prolonging drugs.
No interactions on record
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Levomilnacipran."
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Desvenlafaxine."
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Milnacipran."
PROMETHAZINE HYDROCHLORIDE PLAIN and HYDROXYZINE are distinct pharmacological agents. PROMETHAZINE HYDROCHLORIDE PLAIN belongs to the Antihistamine / Antiemetic class and is primarily used for FDA-approved: Symptomatic management of allergic conditions (e.g., rhinitis, urticaria, pruritus), motion sickness, nausea and vomiting (prevention and treatment), and as a preoperative sedative or adjunct to analgesics.Off-label: Relief of anxiety, insomnia, and as a sedative-hypnotic.. HYDROXYZINE belongs to the Antihistamine class and is primarily used for Pruritus due to allergic conditions such as urticaria, atopic dermatitis, and contact dermatitisAnxiety and tension (as a short-term management in adults)Preoperative sedation and to reduce anxiety prior to surgeryNausea and vomiting (off-label)Insomnia (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. PROMETHAZINE HYDROCHLORIDE PLAIN carries a safety status of Category A/B, whereas HYDROXYZINE safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Extensively metabolized in the liver via oxidation, primarily by CYP2D6, and via N-demethylation and sulfoxidation. Metabolites include promethazine sulfoxide and N-desmethylpromethazine.
Hydroxyzine is primarily metabolized by the liver via CYP3A4 and CYP2D6 isoenzymes. The major active metabolite is cetirizine, which is also a histamine H1 receptor antagonist.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~70% of elimination, with 20-30% as unchanged drug in urine. Fecal excretion is minimal (~5%).
Renal: approximately 70% as metabolites, less than 1% unchanged. Fecal/biliary: minor. Cetirizine (active metabolite) also renally eliminated.
85-93% bound primarily to albumin (HSA), with minor binding to alpha1-acid glycoprotein.
93% bound to plasma proteins, primarily albumin.
Vd ranges from 3-5 L/kg (mean ~4 L/kg) indicating extensive tissue distribution. Clinical meaning: High tissue binding; large loading dose may be needed for rapid effect.
16 L/kg (range 7-20 L/kg), indicating extensive tissue distribution; higher Vd suggests large extravascular binding.
Oral: ~25-40% (extensive first-pass metabolism); IM: ~70-80%; Rectal: ~50-60%; IV: 100%.
Oral: approximately 80%; IM: >80% (almost complete and rapid); IV: 100%.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend dosing interval; Child-Pugh Class C: Avoid use or use lowest dose with caution (e.g., 12.5 mg every 6-12 hours).
Child-Pugh Class B: reduce dose by 50% and/or increase dosing interval to every 12-24 hours. Child-Pugh Class C: use with caution; consider alternative agent or reduce dose by 75% and administer every 24 hours.
Children 2 years and older: 0.5 mg/kg orally or intramuscularly every 6 hours as needed, not to exceed 25 mg per dose (max 50 mg/day); for motion sickness: 0.5 mg/kg given 30-60 minutes before departure, then every 12 hours as needed.
Oral: 2 mg/kg/day in divided doses every 6-8 hours. Maximum: 50 mg/day for children <6 years; 100 mg/day for 6-12 years. IM: 0.5-1 mg/kg every 6-8 hours, not to exceed 50 mg per dose.
Initiate at lower doses (e.g., 12.5 mg orally or intramuscularly every 6-8 hours) due to increased sensitivity to CNS depressant effects, anticholinergic side effects (confusion, urinary retention), and risk of falls; avoid in patients with dementia or cognitive impairment.
Initiate at lowest dose (25 mg orally 3-4 times daily) and titrate cautiously due to increased risk of sedation, confusion, and anticholinergic effects. Maximum recommended dose: 100 mg/day in divided doses.
There is no FDA black box warning for hydroxyzine.
Avoid alcohol and grapefruit juice. Alcohol potentiates sedative effects. Grapefruit juice may increase promethazine levels by inhibiting CYP450 metabolism. No specific food restrictions otherwise.
Hydroxyzine may be taken with or without food. Grapefruit juice may increase hydroxyzine serum concentrations and risk of adverse effects; avoid concurrent consumption. High-fat meals can delay but not significantly reduce absorption. No other food restrictions are required.
Excreted into breast milk; M/P ratio approximately 0.5-1.0. Limited data suggest low risk with occasional use, but may cause sedation, apnea, or irritability in neonate; avoid in breastfeeding mothers of preterm or compromised infants. Monitor infant for drowsiness.
Hydroxyzine is excreted into breast milk in small amounts. The milk-to-plasma ratio is estimated at approximately 0.5. In infants, it may cause sedation, irritability, or poor feeding. Because of the potential for serious adverse reactions in nursing infants, consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for hydroxyzine and any potential adverse effects on the breastfed infant. Alternatives with better safety profiles may be preferred.
No specific dose adjustment required; use lowest effective dose for shortest duration. Increased clearance in pregnancy may theoretically require dose adjustment but no established guidelines; monitor clinical response and adjust accordingly.
Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma albumin, and altered hepatic metabolism) may affect hydroxyzine concentrations. However, specific dose adjustments for pregnancy are not well-established. Clinical monitoring for efficacy and adverse effects is recommended, and using the lowest effective dose for the shortest duration is prudent. No routine dose adjustment is mandated, but individual patient response should guide therapy.
This medication may cause drowsiness, dizziness, and blurred vision. Do not drive or operate heavy machinery until you know how it affects you.,Avoid alcohol and other central nervous system depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness and dizziness.,Take exactly as prescribed. Do not exceed the recommended dose or duration.,If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Do not double the dose.,Contact your healthcare provider if you experience symptoms of extrapyramidal effects (e.g., involuntary muscle movements, restlessness, stiffness) or jaundice.,Keep out of reach of children. Overdose can cause hallucinations, seizures, and cardiorespiratory arrest.,Store at room temperature away from light and moisture. Do not freeze the injection.
Take hydroxyzine exactly as prescribed and do not exceed the recommended dose.,Avoid driving or operating heavy machinery until you know how hydroxyzine affects you, as it may cause drowsiness or dizziness.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, opioids) while taking hydroxyzine.,Notify your doctor if you experience blurred vision, dry mouth, difficulty urinating, or rapid heartbeat.,Do not stop taking hydroxyzine abruptly if using for anxiety; consult your doctor for a taper plan.,Store at room temperature, away from moisture and heat.